IonQ to Increase Performance and Scale of Quantum Computers with Photonic Integrated Circuits in Collaboration with imec
IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today that it is developing photonic integrated circuits (PICs) and chip-scale ion trap technology for trapped ion quantum computing in partnership with imec, a world-renowned R&D center in nanoelectronics and digital technologies. By optimizing the design, production, and integration of chip-scale photonic devices and ion traps for scalable and high-performance quantum computers, the developments aim to push the boundaries of quantum computing performance.
Traditional trapped ion quantum computing approaches rely on bulk optics for laser light modulation, delivery, and photon collection. By moving traditional bulk optical components into integrated photonic devices, IonQ aims to reduce overall hardware system size and cost, increase qubit count, and improve system performance and robustness. Chip-scale optical technologies and IonQ’s tight integration with imec’s trap manufacturing and packing are expected to open up new system capabilities, increase reliability, drive down overall cost-per-qubit, and reduce time to market for new generations of quantum computers.
“Adding imec to IonQ’s set of fabrication and technology partners will have a profound impact on our ability to increase the computational power of our quantum computers through the co-development of compact, high-performance electro-optical systems,” said Dean Kassmann, IonQ’s SVP of Engineering and Technology. “This partnership marks a significant milestone in IonQ’s path to achieving commercial quantum advantage, demonstrating our commitment to combining technical performance improvements with scalability and enterprise-grade solutions.”
Since 2021, IonQ and imec have worked to prototype and refine photonic and ion trap technologies critical to IonQ’s quantum computing roadmap. This expanded engagement aims to develop advanced trap fabrication processes that will allow much richer trap and device functionality in the future.
“We look forward to strengthening an already successful relationship with IonQ and further advancing what’s possible in chip-scale quantum technology,” said Paul Heremans, SVP Industry & Consumer at imec. “We believe imec’s advanced technologies, in particular integrated photonics, have a pivotal role to play in delivering cutting-edge devices for quantum computing.”
Today’s news marks a strengthening of the multi-year relationship between the two companies and is the latest in a series of manufacturing and supply chain announcements from IonQ.
Earlier this year, IonQ opened the United States’ first quantum computing manufacturing facility in Bothell, Washington, which houses the R&D and manufacturing teams responsible for the rollout of IonQ’s next-generation quantum systems. In November, IonQ announced a partnership with NKT Photonics to deliver three innovative prototype optical subsystems to IonQ in 2025. The advanced laser systems will be integrated into IonQ’s upcoming data center-ready quantum systems.
To learn more about IonQ and its latest system news and business developments, visit https://ionq.com/.
About IonQ
IonQ, Inc. is a leader in quantum computing that delivers high-performance systems capable of solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computer, IonQ Forte, is the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Fast Company’s 2023 Next Big Things in Tech List and Deloitte’s 2023 Technology Fast 500™ List, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.
About imec
imec is a world-leading research and innovation center in nanoelectronics and digital technologies. imec leverages its state-of-the-art R&D infrastructure and its team of more than 5,500 employees and top researchers, for R&D in advanced semiconductor and system scaling, silicon photonics, artificial intelligence, beyond 5G communications and sensing technologies, and in application domains such as health and life sciences, mobility, industry 4.0, agrofood, smart cities, sustainable energy, education. imec unites world-industry leaders across the semiconductor value chain, Flanders-based and international tech, pharma, medical and ICT companies, start-ups, and academia and knowledge centers. imec is headquartered in Leuven (Belgium), and has research sites across Belgium, in the Netherlands, the United Kingdom and the USA, and representation in 3 continents. In 2023, imec's revenue (P&L) totaled 941 million euro.
Further information on imec can be found at www.imec-int.com.
IonQ Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the terms “advanced,” “advancing,” “aims,” “believe,” “critical,” “design,” “develop,” “developing,” development,” “expected,” “game-changing technology,” “impact,” “milestone,” “push the boundaries,” “scale,” “scalable,” “reduce,” “towards,” “will,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to IonQ’s quantum computing capabilities and plans, access to IonQ’s quantum computers, the scalability, performance, and reliability of IonQ’s quantum computing offerings, the ability for IonQ’s offerings to accelerate photonic and ion trap technologies, the potential benefits of IonQ’s strategic partnerships, and the advantages of IonQ's approach to the manufacturing of IonQ’s systems. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: changes in laws and regulations affecting IonQ’s business; IonQ’s ability to implement its technical roadmap; the purchase, use and availability of products, components and services supplied by third parties, including third-party IP and manufacturing services; or IonQ’s ability to identify and realize partnerships and opportunities. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107757599/en/
Contacts
IonQ Media contact:
Tyler Ogoshi
press@ionq.com
IonQ Investor Contact:
investors@ionq.co
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Analyze Contracts Like a Lawyer - Wordsmith’s First Pass Unlocks Legal Insight for Everyone7.11.2024 23:54:00 CET | Press Release
“Contracts often hold up business because legal teams are stretched too thin,” said Ross McNairn, CEO of Wordsmith. “First Pass allows anyone from the legal, commercial or other teams to quickly identify risks and key terms, helping move things forward.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241108164624/en/ Wordsmith's First Pass lets you review contracts in minutes, not hours. (Graphic: Business Wire) This is a glimpse at the future of legal AI agents. Taking a very specific task end-to-end and making it trivial for anyone to trigger. Try It for Free Users can access First Pass for free by creating an account at wordsmith.ai and then uploading the relevant agreement to the web, or simply email standard agreements—like NDAs—to nda@wordsmith.ai. Over the coming weeks, Wordsmith will be expanding this to many other agreement types. End-to-End AI Analysis—More Than Just Contracting What makes First Pass revolutionary
Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research7.11.2024 22:01:00 CET | Press Release
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it has signed an agreement to acquire the DNA and RNA business of Officinae Bio. The acquisition is expected to expand Maravai and TriLink BioTechnologies' ability to assist customers in developing innovative nucleic acid-based therapies. Based in Venice, Italy, Officinae Bio is a privately held technology company with a proprietary digital platform to support the biological design of therapeutics. The novel technology enables rapid prototyping of mRNA candidates to test diverse combinations of CAP analogs, chemistry modifications, and sequence designs for client discovery programs. Officinae Bio’s portfolio of technology and services complements Maravai’s nucleic acid production services and is expected to provide customers with significant benefits as they bring new and innovative therapies to patients in need. “Officinae Bio’s uniqu
BM3EAC Corp. Termination of Discussions Regarding Proposed Business Combination With Arkon Energy7.11.2024 18:29:00 CET | Press Release
BM3EAC Corp. (the “Company”), a shell company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., hereby announces the termination of the discussions with Arkon Energy Ohio LLC (now Arkon Energy US Holdco LLC) (“Arkon”) regarding a potential transaction, including a business combination, initially announced on 21 February 2024 (the “Potential Business Combination”). After careful consideration, the Company and Arkon have determined that the current market conditions are not conducive to proceeding with the Potential Business Combination. IMPORTANT INFORMATION This press release may contain information that qualifies or may have qualified as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or s
Brenus Pharma Publishes Promising Proof of Concept Results of their Therapeutic Platform in the Scientific Frontiers in Oncology Journal. (1)7.11.2024 18:00:00 CET | Press Release
Brenus Pharma has announced the publication of a scientific article describing its new “off-the-shelf” cancer treatment in “Frontiers in Oncology” Section Cancer Immunity and Immunotherapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107407975/en/ Brenus’ platform mimics patients’ relapsing conditions in lab, to educate the immune system against tumors evolution with the largest panel of multi-specific targets available. Its lead candidate is a proteomic-guided immunotherapy, designed to treat patients with advanced or metastatic CRC. Results show that the murine surrogate treatment inhibits tumor growth and improves survival of treated mice bearing tumors. It has also shown efficacy in a PD1-resistant model, with an increased infiltration of CD8+T cells in cold tumors, associated with strong safety data. Indeed, the treatment’s in vitro exposition to standards of careinduces the expression of cancer-related proteins l
Sandvine Announces Comprehensive Restructuring Transaction as Part of Ongoing Business Realignment7.11.2024 15:35:00 CET | Press Release
Sandvine Corporation and certain of its affiliates and subsidiaries (“Sandvine” or the “Company”) today announced that it has commenced proceedings under the Companies’ Creditors Arrangement Act (“CCAA”) in the Ontario Superior Court of Justice (Commercial List) and is in the process of commencing a companion recognition proceeding under Chapter 15 of Title 11 of the United States Code (“Chapter 15”) in the United States Bankruptcy Court for the Northern District of Texas (Dallas Division) in order to implement a comprehensive restructuring transaction. On October 2, 2024, the Company entered into a Restructuring Support Agreement (“RSA”) with over 97% of its secured lenders, who are also current shareholders of the Company (“Investors”), to implement a transaction that would result in, among other things, the conversion of the Company’s legacy funded debt obligations into equity and the funding of the Company through a new super senior loan facility under which the Investors provide n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom